IL17A and psoriasis: Further in vivo study with IMQ‐induced psoriasis mice indicates that nor@MSC‐EVs alleviate erythema, scaling, and thickness of skin lesions, showing a more potent therapeutic effect than the currently used clinical bioreagent anti‐IL17A.